Author | Ryan McDonald


KTE-X19 Proves Comparable to Current Therapies in Treating High-Risk MCL

May 31, 2020

When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index.

Cancer Progression Linked to Increased Risk of Death Within 30 Days of COVID-19 Diagnosis

May 28, 2020

Disease progression and treatment with hydroxychloroquine and azithromycin were associated with increased all-cause 30-day mortality in patients with cancer compared to patients either in remission or with no evidence of disease, according to data presented during a 2020 ASCO Virtual Scientific Program press briefing.